Immunotherapy in Head and Neck Cancer

DOI

10.2991/978-94-6463-280-4_3How to use a DOI?

Keywords

malignancy; malignancy in the head and neck

ABSTRACT

Introduction

Head and neck cancer is the 8th with the highest mortality rate and a low 5-year survival rate of 40-50%. In patients who experience recurrence or metastases, especially in nasopharyngeal cancer and are HPV-positive, first-line immunotherapy can be performed through immune checkpoint inhibition using antibodies against programmed death (PD-1) inhibitors. Objective: To know the action of immunotherapy against head and neck cancer cells. Conclusion: The programmed death (PD-1) inhibitor is an immunotherapy technique widely used today in head and neck cancer. As with other therapy modalities in general, it is necessary to pay attention to the side effects of immunotherapy that affect the body in the form of toxicity.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Erick Maulana Yusup
AU  - Yussy Afriani Dewi
PY  - 2023
DA  - 2023/10/31
TI  - Immunotherapy in Head and Neck Cancer
BT  - Proceedings of the 19 th Otorhinolaryngology head and neck surgery national congress (PERHATIKL 2022)
PB  - Atlantis Press
SP  - 11
EP  - 16
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-280-4_3
DO  - 10.2991/978-94-6463-280-4_3
ID  - Yusup2023
ER  -